Skip to main content
Clinical Trials/NCT03182998
NCT03182998CompletedNot Applicable

Testing Decision Aids to Improve Prostate Cancer Decisions for Minority Men

Mayo Clinic5 sites in 1 country103 target enrollmentStarted: July 14, 2017Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
103
Locations
5
Primary Endpoint
Knowledge Assessed by Prostate Cancer Treatment Questionnaire

Study Overview

Brief Summary

This randomized phase III trial studies how well decision aids work in improving knowledge in patients with prostate cancer. Decision aids may improve patients' knowledge of their condition and options for treatment, and may also help when talking with their doctor.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Other
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients must have prostate biopsy within 4 months prior to registration showing newly diagnosed prostate cancer, stage T1-3N0M0; in addition, patients must have: Gleason score 6-10
  • •Prostate-specific antigen (PSA) < 50 ng/mL
  • •Patients who have had a history of non-cutaneous malignancy in the previous 5 years are not eligible; exception: patients with history of non-melanoma skin cancer are eligible
  • •Scheduled prostate cancer consultation to be the first consultation after diagnosis (i.e. not a second-opinion or a consultation following previous discussions of treatment options)
  • •Patients may not be concurrently enrolled to another clinical trial for the treatment of cancer; co-enrollment to biospecimen studies is allowed
  • •Patients with impaired decision-making capacity (such as with a diagnosis of dementia or memory loss) are not eligible for this study
  • •Patients must be able to read and comprehend English; non-English-speaking patients may participate so long as an interpreter (e.g., family member, clinic staff, etc.) is present for consent, for the decision aid administration, and gathering of baseline and follow-up measures

Exclusion Criteria

  • Not provided

Arms & Interventions

Arm C (Usual Care)

Active Comparator

Patients undergo usual care.

Intervention: Best Practice (Other)

Arm C (Usual Care)

Active Comparator

Patients undergo usual care.

Intervention: Quality-of-Life Assessment (Other)

Arm C (Usual Care)

Active Comparator

Patients undergo usual care.

Intervention: Questionnaire Administration (Other)

Arm C (Usual Care)

Active Comparator

Patients undergo usual care.

Intervention: Survey Administration (Other)

Arm C (Usual Care)

Active Comparator

Patients undergo usual care.

Intervention: Laboratory Biomarker Analysis (Other)

Arm A (Knowing Your Options)

Experimental

Arm A ("Knowing your Options") Patients receive "Knowing your Options" decision aid before their consultation visit.

Intervention: Internet-Based Intervention (Other)

Arm A (Knowing Your Options)

Experimental

Arm A ("Knowing your Options") Patients receive "Knowing your Options" decision aid before their consultation visit.

Intervention: Quality-of-Life Assessment (Other)

Arm A (Knowing Your Options)

Experimental

Arm A ("Knowing your Options") Patients receive "Knowing your Options" decision aid before their consultation visit.

Intervention: Questionnaire Administration (Other)

Arm A (Knowing Your Options)

Experimental

Arm A ("Knowing your Options") Patients receive "Knowing your Options" decision aid before their consultation visit.

Intervention: Survey Administration (Other)

Arm A (Knowing Your Options)

Experimental

Arm A ("Knowing your Options") Patients receive "Knowing your Options" decision aid before their consultation visit.

Intervention: Laboratory Biomarker Analysis (Other)

Arm B (Prostate Choice)

Experimental

Patients receive "Prostate Choice" decision aid during their consultation visit.

Intervention: Internet-Based Intervention (Other)

Arm B (Prostate Choice)

Experimental

Patients receive "Prostate Choice" decision aid during their consultation visit.

Intervention: Quality-of-Life Assessment (Other)

Arm B (Prostate Choice)

Experimental

Patients receive "Prostate Choice" decision aid during their consultation visit.

Intervention: Questionnaire Administration (Other)

Arm B (Prostate Choice)

Experimental

Patients receive "Prostate Choice" decision aid during their consultation visit.

Intervention: Survey Administration (Other)

Arm B (Prostate Choice)

Experimental

Patients receive "Prostate Choice" decision aid during their consultation visit.

Intervention: Laboratory Biomarker Analysis (Other)

Outcomes

Primary Outcomes

Knowledge Assessed by Prostate Cancer Treatment Questionnaire

Time Frame: 12 months

The primary outcome, knowledge, will be assessed by a standardized questionnaire (i.e., Prostate Cancer Treatment Questionnaire) administered once, immediately after the clinical consultation while the patient is still at the study site. The number correct from this 12-item measure will be reduced to a proportion of total number correct. With 1.0 (12 out of 12 item average) being the best possible outcome and 0.0 (0 out of 12 item average) the worst possible outcome

Secondary Outcomes

  • Decisional Quality as Measured by Decisional Regret Scale(12 months)
  • Utilization as Determined by Chart Review(12 months)
  • Quality of Life Assessed by Questionnaire(12 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Jon C. Tilburt

Principal Investigator

Mayo Clinic

Study Sites (5)

Loading locations...

Similar Trials